ONCOmmunity

Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort.

By: J Ose, R T Fortner, H Schock, P H Peeters, N C Onland-Moret, H B Bueno-de-Mesquita, E Weiderpass, I T Gram, K Overvad, A Tjonneland, L Dossus, A Fournier, L Baglietto, A Trichopoulou, V Benetou, D Trichopoulos, H Boeing, G Masala, V Krogh, A Matiello, R Tumino, M Popovic, M Obón-Santacana, N Larrañaga, E Ardanaz, M-J Sánchez, V Menéndez, M-D Chirlaque, R C Travis, K-T Khaw, J Brändstedt, A Idahl, E Lundin, S Rinaldi, E Kuhn, I Romieu, M J Gunter, M A Merritt, E Riboli, R Kaaks

Division of Cancer Epidemiology, German Cancer Research Center, 69120 Heidelberg, Germany.
2014-5-28; doi: 10.1038/bjc.2014.566

Abstract

Background:Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics.Methods:We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n=565 cases). Multivariable conditional logistic regression models were used to estimate associations.Results:We observed no association between IGF-I and EOC overall or by tumour characteristics.Conclusions:In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum IGF-I concentrations may not influence EOC risk.British Journal of Cancer advance online publication, 4 November 2014; doi:10.1038/bjc.2014.566.

PMID:25349976